Cholesterol Claim Clarification To Be Covered In Upcoming FDA Guidance
This article was originally published in The Tan Sheet
Executive Summary
"Inconsistencies" in FDA's handling of "philosophically-related" cholesterol claims will be addressed in the agency's upcoming guidance on dietary supplement structure/function claims, the Center for Food Safety & Applied Nutrition's Robert Moore, PhD, told a FDLI meeting on supplement regulation in Washington, D.C. June 26.
You may also be interested in...
OTC Cholesterol Drugs Preferred Over Supplements, NCL Survey Finds
Consumers would use OTC cholesterol-lowering drugs instead of dietary supplements currently marketed as maintaining healthy cholesterol levels, a survey conducted by the National Consumers League finds.
Mason Stands By Cholesterol, Migraine Claims Despite "Courtesy" Letter
Eight supplement makers received FDA "courtesy" letters recently regarding their structure/function claims for cholesterol reduction, the latest in a string of such letters targeting cholesterol claims. One of the firms, Mason Vitamins, is standing by its claims in spite of the March 23 advisory letter from FDA saying they are unapproved drug claims.
Pearson Applies To Both Foods, Supplements - GMA Citizen Petition
FDA should immediately apply the Pearson v. Shalala ruling on health claims to both conventional foods and dietary supplements, the Grocery Manufacturers of America asserts in an April 27 citizen petition, urging the agency to immediately withdraw and revise its implementation plan.